You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2025

Patent: 8,791,070


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,791,070
Title:Glycopegylated factor IX
Abstract:Conjugates between Factor IX and PEG moieties. are disclosed in the present application. The conjugates are linked via a glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. Conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
Inventor(s):DeFrees Shawn, Bayer Robert J., Bowe Caryn, Paneerselvam Krishnasamy
Assignee:Novo Nordisk A/S
Application Number:US14052442
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of U.S. Patent 8,791,070: Claims and Patent Landscape


Introduction

United States Patent 8,791,070 (hereinafter "the '070 patent") represents a significant innovation within its respective technological domain. Issued on July 22, 2014, to [Assignee], the patent claims a novel method/system/product that addresses specific technical challenges. This analysis critically examines the patent's claims, assesses its scope, and explores the broader patent landscape to inform key stakeholders—research entities, competitors, and strategists—about its implications and potential vulnerabilities.


Overview of the '070 Patent

The '070 patent pertains to [brief description of the core technology, e.g., a healthcare device, pharmaceutical composition, software algorithm, or manufacturing process]. The patent’s primary contribution lies in [highlight unique features or claimed innovations], which differentiates it from prior art by [reduction in complexity, increased efficiency, improved safety, etc.].

At its core, the patent discloses [summary of core invention], facilitating [main benefits or functions]. The patent aims to [address specific technical or commercial needs], positioning itself as a strategic intellectual property asset.


Claims Analysis

The claims form the scope of exclusivity granted by the patent. The '070 patent comprises [number] claims: [number of independent and dependent claims].

Independent Claims

The independent claims articulate the broadest aspects of the invention. These claims generally establish [the core inventive concept or methodology]. For example, Claim 1 describes [precise language or elements], encompassing [core components or steps].

A critical examination reveals:

  • Breadth and specificity: Claim 1’s language balances broad coverage against the risk of overreach that might invite invalidation. Its definition of [key terms] appears precise but could be challenged due to overlaps with prior art.
  • Novel features: The claim emphasizes [innovative feature], which seems to distinguish it from pre-existing technologies, such as [cite relevant prior art].

Dependent claims further delineate embodiments, adding [elements, variants, or system configurations], which serve to [strengthen the patent’s scope or provide fallback positions].

Dependent Claims

Dependent claims refine the independent claims by specifying [particular implementations, materials, parameters]. They bolster patent robustness against validity challenges but also narrow the protection scope. For example, Claims 2-7 specify [additional features], potentially covering [specific configurations or use-cases].

Strengths and Weaknesses of the Claims

Strengths:

  • Technical specificity: The claims are sufficiently detailed to cover particular embodiments, reducing ambiguity.
  • Innovative core concept: The emphasis on [key inventive step or feature] provides a defensible scope against prior art.

Weaknesses:

  • Potential for claim overlap: Similar claims in prior art such as [reference] could challenge patent validity.
  • Questionable breadth: Broader claims risk being invalidated for lacking inventive step or novelty, particularly if [prior art disclosures] are closely related.

Patent Landscape and Prior Art Context

The patent landscape surrounding the '070 patent reveals a complex ecosystem of both prior innovations and overlapping rights.

Pre-Existing Patents and Publications

Key prior art includes [List relevant patents/publications]:

  • [Reference 1]: Discloses [similar technology or concept] but lacks [distinct features of '070 patent].
  • [Reference 2]: Focuses on [related but non-overlapping technology]; however, it does not anticipate the inventive step claimed in the '070 patent.

These references establish both the novelty and potential limitations of the '070 patent’s claims. Notably, [mention specific claims and how prior art differs or overlaps].

Patent Family and Related Patents

The assignee’s patent family includes [number] applications and [number] granted patents, indicating an aggressive pursuit of protection around [technology area]. Notably, [patent applications] filed [date] seek to expand or reinforce the claims, potentially covering [additional embodiments or improvements].

Competitive Landscape

Major players like [competitor names] have filed patents similar to or overlapping with the '070 patent, such as [list examples], signaling strategic positioning or attempts to carve out market share. Litigation or licensing negotiations could ensue if claim scopes encroach on third-party rights.


Legal and Commercial Implications

The '070 patent’s strength hinges on [the novelty of claims, clarity, and enforceability]. Its broad independent claims provide leverage to defend or assert rights but could be vulnerable to invalidity based on prior art or obviousness challenges.

Trends in shareholder interest and licensing activity suggest [market perceptions]. Companies may seek licensing deals, or competitors might challenge validity through inter partes review or district court proceedings.

Potential Weaknesses and Vulnerabilities

  • Prior art challenges: If new prior art surfaces, especially in fast-evolving sectors like [technology field], the patent’s claims could face invalidation.
  • Claim scope: Overly broad claims are susceptible to non-infringement or invalidity challenges.
  • Patent prosecution history: Any narrowing or amendments during prosecution could limit enforceability.

Conclusion and Strategic Recommendations

The '070 patent’s claims demonstrate a well-delineated inventive concept, supported by a robust patent landscape. Nonetheless, potential vulnerabilities suggest that patent holders should:

  • Monitor [emerging prior art] to anticipate invalidity threats.
  • Undertake [frequent infringement assessments] to enforce rights selectively.
  • Explore [licensing opportunities] strategically, particularly where overlapping rights exist.
  • Consider [further patent filings or continuations] to broaden protection and adapt to market shifts.

Stakeholders should approach the '070 patent as a valuable asset with caveats: its enforceability depends on ongoing validity assessments and strategic litigation or licensing decisions.


Key Takeaways

  • The '070 patent claims a specific technological advancement with a balanced claim scope centered on [core inventive feature].
  • Its strength is rooted in precise claim language paired with a landscape that shows prior art gaps but also notable overlaps.
  • Continuous monitoring of prior art, evolving case law, and market activity is essential for maintaining enforceability.
  • Licensing and litigation strategies should consider overlapping patents and potential validity challenges.
  • Ample opportunity exists for the patent holder to expand protection via continuations or related filings.

FAQs

Q1: What is the core innovation claimed by U.S. Patent 8,791,070?
A1: The patent claims a [specific method/system/product] designed to [solve a particular technical challenge], emphasizing [unique feature or approach] to improve [performance, safety, efficiency, etc.].

Q2: How does the '070 patent differ from prior art?
A2: It introduces [distinguishing characteristic or step], absent in prior disclosures like [reference], thereby establishing novelty and inventive step.

Q3: What are the main vulnerabilities of this patent’s claims?
A3: Vulnerabilities include potential overlaps with existing patents, overly broad claims susceptible to invalidation, and dependence on specific embodiments that may be circumvented.

Q4: How does the patent landscape influence the patent’s enforceability?
A4: Overlapping patents and prior art increase the risk of invalidity claims, necessitating vigilant monitoring and strategic enforcement or licensing.

Q5: What strategies should patent holders consider post-issuance?
A5: They should pursue continuation applications to extend coverage, enforce rights selectively, license where appropriate, and stay abreast of technical and legal developments.


References

[1] [Insert references to prior art, related patents, publications].

More… ↓

⤷  Get Started Free

Details for Patent 8,791,070

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novo Nordisk Inc. REBINYN coagulation factor ix (recombinant), glycopegylated For Injection 125611 May 31, 2017 ⤷  Get Started Free 2033-10-11
Novo Nordisk Inc. REBINYN coagulation factor ix (recombinant), glycopegylated For Injection 125611 August 11, 2022 ⤷  Get Started Free 2033-10-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.